Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
Completed · Phase 1
Conditions studied: Nonneoplastic Condition
In brief
RATIONALE: Vaccines made from peptides may help the body build an immune response to kill cytomegalovirus. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in preventing cytomegalovirus in healthy participants.
Key facts
- Study ID
- NCT00722839
- Run by
- City of Hope Medical Center
- People needed
- 68
- Starts
- 2006-12-01
- Expected to finish
- 2012-04-01
- Last updated by the study team
- 2012-06-25
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- City of Hope Comprehensive Cancer Center — Duarte, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.